©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Hepatol. Apr 27, 2014; 6(4): 160-168
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.160
Published online Apr 27, 2014. doi: 10.4254/wjh.v6.i4.160
Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease
Agustin Castiella, Eva Zapata, Gastroenterology Service, Mendaro Hospital, Mendaro, 20850 Guipuzcoa, Spain
M Isabel Lucena, Clinical Pharmacology, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, University Hospital Virgen de la Victoria, 29010 Málaga, Spain
Raúl J Andrade, Liver Unit, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga, University Hospital Virgen de la Victoria, 29010 Málaga, Spain
M Isabel Lucena, Raúl J Andrade, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 08036 Barcelona, Spain
Author contributions: All the authors conceived and designed the study, wrote, revised and approved the manuscript.
Correspondence to: Agustin Castiella, PhD, MD, Gastroenterology Service, Mendaro Hospital, Barrio Mendarozabal, 20850 Mendaro, Spain. agustincastiella@yahoo.es
Telephone: +34-94-3032800 Fax: +34-94-3032836
Received: October 26, 2013
Revised: January 9, 2014
Accepted: April 3, 2014
Published online: April 27, 2014
Processing time: 206 Days and 14.2 Hours
Revised: January 9, 2014
Accepted: April 3, 2014
Published online: April 27, 2014
Processing time: 206 Days and 14.2 Hours
Core Tip
Core tip: Drug-induced autoimmune liver disease (DIAILD) is a poorly defined and under-reported liver disorder, and, probably, a underestimated liver disease. A small number of drug-induced liver injury (DILI) cases exhibit features typical of autoimmune hepatitis (AIH). To differentiate between true AIH triggered by drugs (DI-AIH) and immune mediated DILI still remains a challenge. Patients diagnosed with DIAILD have frequently had a previous episode of hepatotoxicity. We consider that some basic requirements are needed to be considered before supporting a drug as a trigger of AIH and they should be taken into account by authors, reviewers and editors when cases are published and made available to the scientific community.